Aug 11, 2025
Data Published in The Laryngoscope shows INO-3107 Resulted in Long-Term Surgery Reduction in Recurrent Respiratory Papillomatosis (RRP)
Aug 04, 2025
INOVIO to Report Second Quarter 2025 Financial Results on August 12, 2025
Jul 07, 2025
INOVIO to Present at Upcoming Scientific Conference
Apr 30, 2025
INOVIO to Present at Upcoming Scientific and Investor Conferences
Apr 09, 2025
INOVIO to Present at Upcoming Scientific Conferences
Mar 18, 2025
INOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights
Mar 13, 2025
INOVIO Announces Promising Interim Results from Ongoing Proof-of-Concept Clinical Trial of DNA-Encoded Monoclonal Antibodies (DMAbs) for COVID-19
Mar 12, 2025
INOVIO to Report Fourth Quarter and Year End 2024 Financial Results on March 18, 2025
Feb 12, 2025
Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as a Treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications
Jan 09, 2025
INOVIO Highlights Anticipated 2025 Milestones and 2024 Key Accomplishments
Dec 03, 2024
New Retrospective Data Shows Half of RRP Patients Treated with INO-3107 Achieved a Complete Response When Evaluated 2 and 3 Years Following Initial Phase 1/2 Trial
Nov 29, 2024
INOVIO Reports Inducement Grant Under Inducement Plan
Nov 14, 2024
INOVIO Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Nov 13, 2024
Immunology Data Shows INOVIO's INO-3107 Induced Expansion of New Clonal T Cells That Infiltrate Airway Tissue and Correspond With Reduction of Surgeries for RRP Patients Observed in Phase 1/2 Trial
Nov 06, 2024
INOVIO to Report Third Quarter 2024 Financial Results on November 14, 2024
Oct 21, 2024
INOVIO Announces New Data at Scientific Conferences for Lead Candidate, INO-3107, as a Potential Treatment for RRP
Sep 17, 2024
INOVIO to Present at Upcoming Scientific Conference
Aug 08, 2024
INOVIO Reports Second Quarter 2024 Financial Results and Recent Business Highlights
Aug 01, 2024
INOVIO Reports Inducement Grant Under Inducement Plan
Jul 25, 2024
Inovio Receives Advanced Therapy Medicinal Product Certificate from European Medicines Agency for Quality and Non-Clinical Data for Lead Candidate INO-3107